tiprankstipranks
Advertisement
Advertisement
BridgeBio Pharma files $500M mixed securities shelf
PremiumThe FlyBridgeBio Pharma files $500M mixed securities shelf
10d ago
BridgeBio Oncology price target lowered to $25 from $27 at JPMorgan
Premium
The Fly
BridgeBio Oncology price target lowered to $25 from $27 at JPMorgan
26d ago
Analyst Maintains Buy Rating on BridgeBio Oncology Therapeutics, Reaffirming Unchanged $23 Price Target Ahead of Key 2026 KRAS Data Catalysts
Premium
Ratings
Analyst Maintains Buy Rating on BridgeBio Oncology Therapeutics, Reaffirming Unchanged $23 Price Target Ahead of Key 2026 KRAS Data Catalysts
30d ago
BridgeBio Oncology assumed with an Outperform at Oppenheimer
PremiumThe FlyBridgeBio Oncology assumed with an Outperform at Oppenheimer
3M ago
John Newman Reiterates Buy on BridgeBio Oncology Therapeutics, Sets $23 Price Target on Differentiated KRAS G12C Profile
Premium
Ratings
John Newman Reiterates Buy on BridgeBio Oncology Therapeutics, Sets $23 Price Target on Differentiated KRAS G12C Profile
3M ago
BridgeBio Oncology’s New ERP Rollout Poses Significant Operational and Reporting Risks
Premium
Company Announcements
BridgeBio Oncology’s New ERP Rollout Poses Significant Operational and Reporting Risks
4M ago
BridgeBio Oncology Overhauls Leadership for Next Development Phase
PremiumCompany AnnouncementsBridgeBio Oncology Overhauls Leadership for Next Development Phase
5M ago
BridgeBio Oncology appoints Pedro Beltran as CEO, Idan Elmelech as COO
Premium
The Fly
BridgeBio Oncology appoints Pedro Beltran as CEO, Idan Elmelech as COO
5M ago
BridgeBio Oncology announces FDA Fast Track Designation for BBO-11818
Premium
The Fly
BridgeBio Oncology announces FDA Fast Track Designation for BBO-11818
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100